[go: up one dir, main page]

WO2015130810A3 - Compositions and methods for the treatment of her2/neu over-expressing tumors - Google Patents

Compositions and methods for the treatment of her2/neu over-expressing tumors Download PDF

Info

Publication number
WO2015130810A3
WO2015130810A3 PCT/US2015/017559 US2015017559W WO2015130810A3 WO 2015130810 A3 WO2015130810 A3 WO 2015130810A3 US 2015017559 W US2015017559 W US 2015017559W WO 2015130810 A3 WO2015130810 A3 WO 2015130810A3
Authority
WO
WIPO (PCT)
Prior art keywords
her2
methods
compositions
treatment
expressing tumors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2015/017559
Other languages
French (fr)
Other versions
WO2015130810A2 (en
Inventor
Vafa Shahabi
Anu Wallecha
Paulo C. Maciag
Yvonne Paterson
Nicola Mason
Matthew Seavey
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Pennsylvania Penn
Ayala Pharmaceuticals Inc
Original Assignee
University of Pennsylvania Penn
Advaxis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US14/189,008 external-priority patent/US20150366955A9/en
Priority claimed from US14/268,436 external-priority patent/US20140234370A1/en
Priority to EP15755609.3A priority Critical patent/EP3110942A4/en
Priority to KR1020167025517A priority patent/KR20160122829A/en
Priority to SG11201607036XA priority patent/SG11201607036XA/en
Priority to KR1020247007406A priority patent/KR20240038103A/en
Priority to NZ723750A priority patent/NZ723750B2/en
Priority to CA2940646A priority patent/CA2940646A1/en
Priority to RU2016137834A priority patent/RU2016137834A/en
Priority to MX2016011114A priority patent/MX2016011114A/en
Priority to JP2016553897A priority patent/JP2017507943A/en
Priority to AU2015223136A priority patent/AU2015223136A1/en
Priority to BR112016019534A priority patent/BR112016019534A2/en
Priority to CN201580010568.4A priority patent/CN106661538A/en
Application filed by University of Pennsylvania Penn, Advaxis Inc filed Critical University of Pennsylvania Penn
Priority to US15/121,421 priority patent/US20160361401A1/en
Priority to US14/669,629 priority patent/US10016617B2/en
Priority to EP15786740.9A priority patent/EP3137107A4/en
Priority to JP2017509588A priority patent/JP2017514904A/en
Priority to AU2015253737A priority patent/AU2015253737A1/en
Priority to CA2947677A priority patent/CA2947677A1/en
Priority to KR1020167033949A priority patent/KR20170002552A/en
Priority to PCT/US2015/024048 priority patent/WO2015167748A1/en
Priority to SG11201609135VA priority patent/SG11201609135VA/en
Priority to MA039942A priority patent/MA39942A/en
Priority to CN201580036168.0A priority patent/CN106794234A/en
Priority to MX2016014367A priority patent/MX2016014367A/en
Publication of WO2015130810A2 publication Critical patent/WO2015130810A2/en
Publication of WO2015130810A3 publication Critical patent/WO2015130810A3/en
Priority to IL247436A priority patent/IL247436A0/en
Anticipated expiration legal-status Critical
Priority to IL248704A priority patent/IL248704A0/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001103—Receptors for growth factors
    • A61K39/001106—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ErbB4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

This invention provides compositions and methods for treating and vaccinating against a HER2/neu antigen-expressing tumor and inducing an immune response against the same in a subject.
PCT/US2015/017559 2009-11-11 2015-02-25 Compositions and methods for the treatment of her2/neu over-expressing tumors Ceased WO2015130810A2 (en)

Priority Applications (26)

Application Number Priority Date Filing Date Title
US15/121,421 US20160361401A1 (en) 2009-11-11 2015-02-25 Compositions and methods for the treatment of her2/neu over-expressing tumors
RU2016137834A RU2016137834A (en) 2014-02-25 2015-02-25 COMPOSITIONS AND METHODS FOR TREATING TUMORS SUPERPRESSING HER2 / neu
MX2016011114A MX2016011114A (en) 2014-02-25 2015-02-25 Compositions and methods for the treatment of her2/neu over-expressing tumors.
SG11201607036XA SG11201607036XA (en) 2014-02-25 2015-02-25 Compositions and methods for the treatment of her2/neu over-expressing tumors
KR1020247007406A KR20240038103A (en) 2014-02-25 2015-02-25 Compositions and methods for the treatment of her2/neu over-expressing tumors
NZ723750A NZ723750B2 (en) 2015-02-25 Compositions and methods for the treatment of her2/neu over-expressing tumors
CA2940646A CA2940646A1 (en) 2014-02-25 2015-02-25 Compositions and methods for the treatment of her2/neu over-expressing tumors
EP15755609.3A EP3110942A4 (en) 2014-02-25 2015-02-25 Compositions and methods for the treatment of her2/neu over-expressing tumors
KR1020167025517A KR20160122829A (en) 2014-02-25 2015-02-25 Compositions and methods for the treatment of her2/neu over-expressing tumors
JP2016553897A JP2017507943A (en) 2014-02-25 2015-02-25 Compositions and methods for the treatment of HER2 / NEU overexpressing tumors
AU2015223136A AU2015223136A1 (en) 2014-02-25 2015-02-25 Compositions and methods for the treatment of HER2/Neu over-expressing tumors
BR112016019534A BR112016019534A2 (en) 2014-02-25 2015-02-25 methods of treating tumor growth and eliciting an enhanced immune response against tumor growth
CN201580010568.4A CN106661538A (en) 2014-02-25 2015-02-25 Compositions and methods for treating HER2/NEU overexpressing tumors
US14/669,629 US10016617B2 (en) 2009-11-11 2015-03-26 Combination immuno therapy and radiotherapy for the treatment of Her-2-positive cancers
CN201580036168.0A CN106794234A (en) 2014-05-02 2015-04-02 Combination Immunotherapy and Radiation Therapy for HER‑2 Positive Cancers
EP15786740.9A EP3137107A4 (en) 2014-05-02 2015-04-02 Combination immuno therapy and radiotherapy for the treatment of her-2-positive cancers
MX2016014367A MX2016014367A (en) 2014-05-02 2015-04-02 Combination immuno therapy and radiotherapy for the treatment of her-2-positive cancers.
MA039942A MA39942A (en) 2014-05-02 2015-04-02 Combination immuno therapy and radiotherapy for the treatment of her-2-positive cancers
AU2015253737A AU2015253737A1 (en) 2014-05-02 2015-04-02 Combination immuno therapy and radiotherapy for the treatment of Her-2-positive cancers
CA2947677A CA2947677A1 (en) 2014-05-02 2015-04-02 Combination immuno therapy and radiotherapy for the treatment of her-2-positive cancers
KR1020167033949A KR20170002552A (en) 2014-05-02 2015-04-02 Combination immuno therapy and radiotherapy for the treatment of her-2-positive cancers
PCT/US2015/024048 WO2015167748A1 (en) 2014-05-02 2015-04-02 Combination immuno therapy and radiotherapy for the treatment of her-2-positive cancers
SG11201609135VA SG11201609135VA (en) 2014-05-02 2015-04-02 Combination immuno therapy and radiotherapy for the treatment of her-2-positive cancers
JP2017509588A JP2017514904A (en) 2014-05-02 2015-04-02 Combined immunotherapy and radiation therapy for the treatment of HER2-positive cancer
IL247436A IL247436A0 (en) 2014-02-25 2016-08-23 Compositions and methods for the treatment of her2/neu over-expressing tumors
IL248704A IL248704A0 (en) 2014-05-02 2016-11-02 Combination immuno therapy and radiotherapy for the treatment of her-2-positive cancers

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US14/189,008 US20150366955A9 (en) 2009-11-11 2014-02-25 Compositions and methods for prevention of escape mutation in the treatment of her2/neu over-expressing tumors
US14/189,008 2014-02-25
US14/268,436 US20140234370A1 (en) 2009-11-11 2014-05-02 Compositions and methods for prevention of escape mutation in the treatment of her2/neu over-expressing tumors
US14/268,436 2014-05-02
US201462076411P 2014-11-06 2014-11-06
US62/076,411 2014-11-06

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US14/268,436 Continuation US20140234370A1 (en) 2008-05-19 2014-05-02 Compositions and methods for prevention of escape mutation in the treatment of her2/neu over-expressing tumors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US12/945,386 Continuation-In-Part US9084747B2 (en) 2008-05-19 2010-11-12 Compositions and methods for prevention of escape mutation in the treatment of HER2/NEU over-expressing tumors

Publications (2)

Publication Number Publication Date
WO2015130810A2 WO2015130810A2 (en) 2015-09-03
WO2015130810A3 true WO2015130810A3 (en) 2016-01-28

Family

ID=54009773

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2015/017559 Ceased WO2015130810A2 (en) 2009-11-11 2015-02-25 Compositions and methods for the treatment of her2/neu over-expressing tumors

Country Status (12)

Country Link
EP (1) EP3110942A4 (en)
JP (1) JP2017507943A (en)
KR (2) KR20160122829A (en)
CN (1) CN106661538A (en)
AU (1) AU2015223136A1 (en)
BR (1) BR112016019534A2 (en)
CA (1) CA2940646A1 (en)
IL (1) IL247436A0 (en)
MX (1) MX2016011114A (en)
RU (1) RU2016137834A (en)
SG (1) SG11201607036XA (en)
WO (1) WO2015130810A2 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9012141B2 (en) 2000-03-27 2015-04-21 Advaxis, Inc. Compositions and methods comprising KLK3 of FOLH1 antigen
WO2012125551A1 (en) 2011-03-11 2012-09-20 Advaxis Listeria-based adjuvants
EP2825195A4 (en) 2012-03-12 2015-10-07 Advaxis Inc INHIBITION OF FUNCTION OF SUPPRESSOR CELLS AFTER TREATMENT WITH LISTERIA-BASED VACCINE
MX2016010791A (en) 2014-02-18 2017-04-27 Advaxis Inc Biomarker directed multi-target immunotherapy.
MA39717A (en) * 2014-03-05 2017-01-11 Advaxis Inc METHODS AND COMPOSITIONS FOR INCREASING THE RATIO OF T EFFECTOR LYMPHOCYTES TO REGULATORY T LYMPHOCYTES
MA39849A (en) 2014-04-24 2017-03-01 Advaxis Inc Recombinant listeria vaccine strains and methods of producing the same
MA41644A (en) 2015-03-03 2018-01-09 Advaxis Inc LISTERIA-BASED COMPOSITIONS INCLUDING A MINIGEN EXPRESSION SYSTEM CODING PEPTIDES, AND METHODS OF USE THEREOF
CN108601731A (en) 2015-12-16 2018-09-28 磨石肿瘤生物技术公司 Identification, manufacture and use of neoantigens
MX2019005685A (en) 2016-11-30 2019-09-04 Advaxis Inc Immunogenic compositions targeting recurrent cancer mutations and methods of use thereof.
KR102748132B1 (en) 2017-09-19 2025-01-02 어드박시스, 인크. Composition and method for freeze-drying of bacterial or listeria strains
EP4576103A3 (en) 2017-10-10 2025-08-27 Gritstone bio, Inc. Neoantigen identification using hotspots
EP3714275A4 (en) 2017-11-22 2021-10-27 Gritstone bio, Inc. REDUCTION OF CONNECTING EPITOPES FOR NEOANTIGENS

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020025323A1 (en) * 2000-03-29 2002-02-28 Yvonne Paterson Compositions and methods for enhancing immunogenicity of antigens
US20120014984A1 (en) * 2009-11-11 2012-01-19 Vafa Shahabi Compositions and methods for prevention of escape mutation in the treatment of her2/neu over-expressing tumors

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020025323A1 (en) * 2000-03-29 2002-02-28 Yvonne Paterson Compositions and methods for enhancing immunogenicity of antigens
US20120014984A1 (en) * 2009-11-11 2012-01-19 Vafa Shahabi Compositions and methods for prevention of escape mutation in the treatment of her2/neu over-expressing tumors

Also Published As

Publication number Publication date
KR20240038103A (en) 2024-03-22
IL247436A0 (en) 2016-11-30
WO2015130810A2 (en) 2015-09-03
KR20160122829A (en) 2016-10-24
RU2016137834A (en) 2018-03-29
CA2940646A1 (en) 2015-09-03
JP2017507943A (en) 2017-03-23
MX2016011114A (en) 2017-02-20
EP3110942A2 (en) 2017-01-04
CN106661538A (en) 2017-05-10
AU2015223136A1 (en) 2016-09-22
BR112016019534A2 (en) 2017-10-24
EP3110942A4 (en) 2017-08-30
SG11201607036XA (en) 2016-09-29
NZ723750A (en) 2024-02-23

Similar Documents

Publication Publication Date Title
WO2015130810A3 (en) Compositions and methods for the treatment of her2/neu over-expressing tumors
IL265755A (en) Chimeric antigen receptors for the treatment of cancer
IL264674B1 (en) Anti-siglec-7 antibodies for the treatment of cancer
WO2016070051A3 (en) Combination therapy for treatment of disease
EP3538130A4 (en) Immunotherapeutic tumor treatment method
ZA201708265B (en) Tigit-binding agents and uses thereof
MX2017004715A (en) Humanized anti-ox40 antibodies and uses thereof.
HK1248758A1 (en) Listeria-based compositions comprising a peptide minigene expression system and methods of use thereof
WO2016100985A3 (en) Chimeric antigen receptors and methods of use thereof
EP3399982A4 (en) Anti-egfr combinations for treating tumors
TN2016000559A1 (en) Monoclonal antibodies against her2 epitope and methods of use thereof
TW201613647A (en) Compounds and compositions for treating HER2 positive tumors
MA39909A (en) Igf-1r antibody-drug-conjugate and its use for the treatment of cancer
LT4339615T (en) Anti-pd-1 antibodies for use in the treatment of cancer
ZA201900960B (en) Methods and compositions for the treatment of cancer
WO2017049038A3 (en) Anti-cd115 antibodies
ZA202204223B (en) Vaccination with mica/b alpha 3 domain for the treatment of cancer
IL290130A (en) Treatment of immune evasive tumors
WO2017040666A3 (en) Combination therapy for treatment of disease
IL263562A (en) Methods and compositions for prostate cancer diagnosis and treatment
IL280468A (en) Immune modifying particles for the treatment of cancer
WO2015139020A3 (en) Vaccine compositions and methods for restoring nkg2d pathway function against cancers
ZA201808232B (en) Compositions and methods for the treatment of cancer
HK1232563A1 (en) Compositions and methods for the treatment of her2/neu over-expressing tumors
WO2015175599A3 (en) Immunotherapy with binding agents

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15755609

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 247436

Country of ref document: IL

ENP Entry into the national phase

Ref document number: 2016553897

Country of ref document: JP

Kind code of ref document: A

Ref document number: 2940646

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 15121421

Country of ref document: US

Ref document number: MX/A/2016/011114

Country of ref document: MX

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112016019534

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 20167025517

Country of ref document: KR

Kind code of ref document: A

REEP Request for entry into the european phase

Ref document number: 2015755609

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2015755609

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2015223136

Country of ref document: AU

Date of ref document: 20150225

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2016137834

Country of ref document: RU

Kind code of ref document: A

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15755609

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 112016019534

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20160824

WWW Wipo information: withdrawn in national office

Ref document number: 723750

Country of ref document: NZ